A5069772690- Inflammatory Bowel Disease
- Microscopic Colitis
- Helicobacter pylori-related gastroenterology studies
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Esophagitis
- Clostridium difficile and Clostridium perfringens research
- Tuberculosis Research and Epidemiology
- Colorectal Cancer Screening and Detection
- Mycobacterium research and diagnosis
- Autoimmune and Inflammatory Disorders
- Adolescent and Pediatric Healthcare
- Acute Lymphoblastic Leukemia research
- Gastrointestinal disorders and treatments
- Biosimilars and Bioanalytical Methods
- Pharmaceutical studies and practices
- Heparin-Induced Thrombocytopenia and Thrombosis
- Gastric Cancer Management and Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Systemic Lupus Erythematosus Research
- Psoriasis: Treatment and Pathogenesis
- Medication Adherence and Compliance
- Gastrointestinal motility and disorders
- Radiomics and Machine Learning in Medical Imaging
- Potassium and Related Disorders
- Blood disorders and treatments
Bellvitge University Hospital
2011-2023
Institut d'Investigació Biomédica de Bellvitge
2011-2021
Hospital Universitario de La Princesa
2019
Ajuntament de L’Hospitalet
2018
Groupe d'Étude Thérapeutique des Affections Inflammatoires du Tube Digestif
2018
Semmelweis University
2014
Effectiveness of vedolizumab in real world clinical practice is unknown.To evaluate the short and long-term effectiveness patients with inflammatory bowel disease (IBD).Patients who received at least 1 induction dose were included. was defined based on Harvey-Bradshaw index (HBI) Crohn's (CD) Partial Mayo Score (PMS) ulcerative colitis (UC). Short-term response assessed week 14. Variables associated short-term remission identified by logistic regression analysis. The Kaplan-Meier method used...
Summary Background Onset during old age has been reported in upto 10% of total cases inflammatory bowel disease ( IBD ). Aim To evaluate phenotypic characteristics and the use therapeutic resources patients with elderly onset . Methods Case‐control study including all those diagnosed over 60 years since 2000 who were followed‐up for >12 months, identified from databases. Elderly compared aged 18 to 40 at diagnosis, matched by year gender type (adult‐onset). Results One thousand three...
Background & Aims: Despite the negative results of blocking IL-17 in Crohn's disease (CD) patients, selective modulation Th17-dependent responses warrants further study. Inhibition retinoic acid-related orphan receptor gamma (RORɣt), master regulator Th17 signature, is currently being explored inflammatory diseases. Our aim was to determine effect a novel oral RORɣt antagonist (BI119) human CD and on an experimental model intestinal inflammation. Methods: 51 patients 11 healthy subjects were...
Objectives: Mobile apps are useful tools in e-health and self-management strategies disease monitoring. We evaluated the Harvey–Bradshaw index (HBI) mobile app self-administered by patient to see if its results agreed with HBI in-clinic assessed a physician. Methods: Patients were enrolled 4-month prospective study clinical assessments at months 1 4. completed within 48 h, was performed physician (gold standard). scores characterized Crohn's (CD) as remission <5 or active ≥5. determined...
Background The faecal immunochemical test (FIT) is used in colorectal cancer (CRC) screening and for the detection of advanced neoplasia (AN) symptomatic patients, but its accuracy could be improved. Our objective was to assess impact proton pump inhibitors (PPI) on FIT AN, namely adenoma CRC. Methods findings We performed a prospective study 1002 individuals referred diagnostic colonoscopy at Bellvitge University Hospital from September 2011 through October 2012. An exhaustive interview by...
Immunosuppressant therapies (IMTs; thiopurines, anti-tumor necrosis factor agents) may influence the immunologic control of cancer and might facilitate spread recurrence cancer. This study assesses impact use IMTs on development incident cancers (recurrent or new) in patients with inflammatory bowel disease (IBD) a history malignancy.Patients IBD included ENEIDA registry without being exposed to were identified retrospectively reviewed compared regarding further treatment not by means...
Faecal microbiota transplantation (FMT) is an effective and safe treatment of recurrent Clostridioides difficile infection. It essential to make every effort perform FMT rigorously based on scientific knowledge. Selection the faecal donor a key part process ensure recipient safety. Protocols action must be implemented that allow clinicians act with maximum guarantees minimise risks procedure. In this regard, multidisciplinary working group has been set up aim establishing recommendations for...
Loss of response (LOR) to tumour necrosis factor antagonists occurs in up 50% patients with inflammatory bowel disease (IBD). Immunogenicity is a common cause loss due the formation antibodies directed against drug. The ability predict which are likely lose would allow therapies be tailored patient's characteristics. In recent study from PANTS consortium, HLA-DQA1*05 allele identified at increased risk immunogenicity (Sazonovs A et al. JCC 2018; 12(S1): S009–010). aim our work was know...
Patients with inflammatory bowel disease who achieve remission anti-tumour necrosis factor (anti-TNF) drugs may have treatment withdrawn due to safety concerns and cost considerations, but there is a lack of prospective, controlled data investigating this strategy. The primary study aim compare the rates clinical at 1 year in patients discontinue anti-TNF versus those continue treatment.This an ongoing, double-blind, multicentre, randomized, placebo-controlled Crohn's or ulcerative colitis...
Abstract Background Blood loss from the gastrointestinal (GI) tract is most common cause of iron deficiency anaemia (IDA) in adult men and postmenopausal women. Gastroduodenal endoscopy (GDE) colonoscopy are frequently recommended, despite uncertainty regarding coexistence lesions upper lower GI tract. The faecal immunochemical test (FIT) measures concentration haemoglobin (f-Hb) originating only colon or rectum. We aimed to assess whether FIT was able select best endoscopic procedure for...
Abstract Background Loss of response (LOR) to tumour necrosis factor antagonists (anti-TNF) occurs in up 50% patients with inflammatory bowel disease (IBD). The ability predict which are likely lose would allow therapies be tailored the patient’s characteristics. Immunogenicity is a common cause LOR. Recently, GWAS performed using PANTS cohort demonstrated that carriage one or more HLA-DQA1*05 alleles confers an increased risk immunogenicity anti-TNF therapy (Sazonovs et al. Gastroenterology...
Abstract Background HLA-DQA1*05 Carriage is associated with development of anti-drug antibodies to infliximab in patients With Crohn’s Disease (Sazonovs et al. Gastroenterology 2019). Our group has shown that the presence this allele also an independent predictor secondary loss response (Guardiola J, ECCO 2019) and adalimumab J 2020). However, impact HLA-DQA1 * 05 on initial persistence IFX first months treatment unknown. Methods This a retrospective cohort study from prospectively...
Faecal microbiota transplantation (FMT) is an effective and safe treatment of recurrent Clostridioides difficile infection. It essential to make every effort perform FMT rigorously based on scientific knowledge. Selection the faecal donor a key part process ensure recipient safety. Protocols action must be implemented that allow clinicians act with maximum guarantees minimise risks procedure. In this regard, multidisciplinary working group has been set up aim establishing recommendations for...
Background: Anti-TNF trough levels have been associated with clinical outcomes in inflammatory bowel disease (IBD). Several therapeutic algorithms based on drug monitoring proposed. Such require knowing the optimal level window. However, there are few data about which of Adalimumab (ADA) remission. The aim this study was to evaluate relationship between ADA (ADA-TL) and faecal calprotectin (FC) determine ADA-TL biological remission (BR). Methods: Prospective observational including IBD...
Vedolizumab (VDZ) is a monoclonal antibody that blocks integrin α4β7 preventing the migration of lymphocytes to intestinal wall, recently approved for Crohn’s disease (CD) and ulcerative colitis (UC), so scarce data are available in clinical practice. All patients with CD UC treated VDZ five Spanish hospitals were retrospectively identified. Clinical biochemical at baseline during treatment recorded. In total, 107 included (58 CD, 49 UC). Among patients, 67% had extensive UC. location was...
Mobile Applications represent a promising tool to facilitate self-management as new model of health care delivery for IBD. The MediCrohn study was designed evaluate the diagnostic performance Harvey–Bradshaw index (HBI) self-administered by Crohn disease (CD) patients through App, compared with original HBI questionnaire assessed gastroenterologist in clinic (reference). multicentre, prospective study, including CD patients, aged 18+, diagnosis >6 months and familiar technologies who were...
Abstract Background INFEII registry (ClinicalTrials.gov: NCT02904590) is a prospective study promoted by GETECCU to determine the incidence and risk factors of infection in an inception cohort IBD patients. Despite preventive measures recommendations scientific societies, TB remains problem patients with treated immunosuppressants (IMM) biologics. AIMS To asses: (1) screening performed at time inclusion patient registry, (2) latent TB; (3) compliance national European recommendations....